HomeNewsIndiaCoronavirus pandemic | ITI, DRDO to sign pact for producing portable ventilators
Trending Topics

Coronavirus pandemic | ITI, DRDO to sign pact for producing portable ventilators

The company expects to start production of the ventilators in about two-and-a-half months from the date of signing of the memorandum of understanding and technology transfer of the ventilator technology to it from the DRDO.

April 09, 2020 / 20:26 IST
Story continues below Advertisement
Representative image
Representative image

Electronics manufacturing company ITI Limited and the Defence Research and Development Organisation (DRDO) are set to sign an agreement for the manufacturing of portable ventilators, a top official of the public sector firm said on Thursday.

The company expects to start production of the ventilators in about two-and-a-half months from the date of signing of the memorandum of understanding and technology transfer of the ventilator technology to it from the DRDO.

Story continues below Advertisement

"We are going to sign a memorandum of understanding with DRDO in the next 2-3 days for the transfer of technology for portable ventilators. We will get 80-90 per cent components locally and the rest will have to be imported. We expect to start manufacturing ventilators in the Bengaluru plant in two-and-a-half months from the date of technology transfer," ITI Chairman and Managing Director RM Agarwal told PTI.

He said that the cost of ventilators will depend on the size of the order that the PSU will get. "The cost of ventilators that we will produce will be lower than units of the same quality. Being a PSU, we will not charge high margins. The final cost cannot be estimated at present because the cost of components for low volume production will be high and less for high volume production. Once DRDO transfers technology, we will start working on material cost and orders," Agarwal said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show